Where Is Psilocybin Therapy Legal? Every State's Status in 2026

Last updated: July 14, 2026 — Mid-year refresh: Connecticut signs its expanded psychedelics pilot into law, Colorado adds an ibogaine research pilot, Minnesota's therapy program stalls at the finish line (a feasibility study passed instead), Virginia's trigger law is signed, and positive 26-week COMP360 results put a final FDA submission on track for Q4 2026.

If you've been following the psychedelic therapy space, you know things are moving fast. Just a few years ago, the idea of walking into a licensed facility and legally receiving psilocybin — the active compound in "magic mushrooms" — seemed like science fiction. In 2026, it's reality in multiple states, and the rest of the country is paying close attention.

This guide breaks down exactly where psilocybin therapy is legal right now, where it's coming soon, and what the federal landscape looks like heading into what could be a pivotal year for psychedelic medicine.

The Big Picture: 2026 Is a Turning Point

The momentum behind psilocybin therapy in the United States is unlike anything the psychedelic space has seen since the 1960s — except this time, it's being driven by clinical data, state legislatures, and federal regulators rather than counterculture movements.

Here's a snapshot of where things stand as of mid-July 2026:

• Two states (Oregon and Colorado) have fully operational, licensed psilocybin therapy programs
• One state (New Mexico) has signed a medical psilocybin law and is building its regulatory framework
• New Jersey signed a psilocybin therapy pilot program into law in January 2026, with $6 million in hospital-based funding (Source: New Jersey Legislature)
• South Dakota passed psilocybin therapy legislation in March 2026
• Connecticut signed an expanded psychedelic therapy pilot program into law on June 4, 2026, and Virginia signed an FDA-triggered rescheduling law on April 13, 2026
• Minnesota passed a psilocybin therapy program through its full House on a 114-15 vote in May, though the program was cut in final budget negotiations — the state instead ordered a feasibility study due January 15, 2027
• 26+ states have introduced psychedelic reform legislation in either the 2025 or 2026 session
• President Trump signed Executive Order 14401 in April 2026, directing the FDA to prioritize psychedelic therapies with Breakthrough Therapy designation — and on April 24, the FDA issued priority review vouchers to three psychedelic programs
• The DEA transmitted a psilocybin rescheduling petition to HHS in August 2025
• COMPASS Pathways has completed two successful Phase 3 clinical trials for its COMP360 psilocybin therapy and reported positive 26-week durability results on July 7, 2026 — the final dataset for its FDA submission, now targeted for Q4 2026, with a potential approval decision by late 2026 or early 2027

That last point is especially significant. If COMP360 receives FDA approval, it would become the first classic psychedelic available as a prescription medicine in the United States — transforming psilocybin therapy from a state-by-state experiment into a nationally accessible treatment option.

Public interest in psilocybin therapy surged again in late March 2026 after CNN aired a feature on psilocybin retreats on March 28, driving a spike in search traffic around legal access, state-by-state status, and how to find a provider. If you landed on this page from that coverage — or from anywhere else — this is the most current and comprehensive state-by-state reference available. We update it as new legislation passes and regulatory frameworks evolve.

But we're getting ahead of ourselves. Let's walk through the states that are already making psilocybin therapy a reality.

---

2026 Legislative Update (Through July 14)

State-level activity accelerated again in the first half of 2026. Here's a quick rundown of the developments shaping the psilocybin legal map this year:

• Connecticut: Governor Ned Lamont signed SB 191 into law on June 4, 2026, expanding the state's psychedelic-assisted therapy pilot program. The law opens eligibility to adults 18 and older who meet clinical criteria (previously limited to veterans and first responders), places the program under a state medical school within FDA-approved research, and removes the provision that would have ended the program upon federal approval. It passed the Senate 35-0 and the House 122-27. (Bill status: Connecticut General Assembly)
• Colorado: HB26-1325 was signed into law on June 4, 2026, establishing an ibogaine research pilot program (up to five sites) within the state's Behavioral Health Administration and authorizing rulemaking for ibogaine in the regulated natural medicine program. The law takes effect August 12, 2026. Details below in the Colorado section.
• Virginia: Governor Abigail Spanberger signed HB 1347 / SB 379 on April 13, 2026, directing the Board of Pharmacy to reschedule FDA-approved psilocybin formulations consistent with federal scheduling — a "trigger law" that activates upon FDA approval. (Source: Virginia General Assembly)
• Minnesota: After the full House adopted a psilocybin therapy program on a 114-15 floor vote in May, the program was dropped in final negotiations between the chambers. What survived: a directive to the Office of Cannabis Management to conduct a feasibility study, with a legislative report due January 15, 2027, outlining a framework for a therapeutic psilocybin program (Minnesota Reformer, July 10, 2026).
• New York: A Psilocybin Assisted Therapy Pilot Program Act was introduced in the 2026 legislative session, marking New York's first comprehensive psilocybin therapy bill.
• Iowa: Psilocybin regulation is under active consideration in the 2026 session, with a regulated program bill modeled on an ALEC template (Reason Foundation, March 2026).
• Missouri: Veterans-focused psilocybin legislation has been introduced in 2026, targeting PTSD and related conditions (Reason Foundation, March 2026).
• Utah: Active psilocybin legislation was noted in MAPS's Q1 2026 legislative wrap-up, continuing the state's incremental research-oriented approach.
• New Mexico: On track for a December 2026 healing center launch, with the state Department of Health targeting initial patient sessions ahead of the statutory deadline.

On the federal side, the first half of 2026 brought Executive Order 14401, priority review vouchers for three psychedelic programs, positive 26-week COMP360 data, final FDA guidance for psychedelic clinical trials, and an HHS–VA partnership on psychedelic therapies for veterans — all covered in the Federal Landscape section below and tracked in detail in our psilocybin FDA approval tracker.

---

Q1 2026 Update: New Jersey Signs Pilot Program, Minnesota Advances Legalization Bill

Updated March 31, 2026

The first quarter of 2026 brought a wave of state-level activity — the most significant being New Jersey's signed pilot program and Minnesota's advancing legalization bill. South Dakota also passed legislation in early March, and several other states introduced noteworthy bills.

New Jersey: Governor Signs Psilocybin Therapy Pilot Program (January 21, 2026)

New Jersey became the first state to launch a hospital-based psilocybin therapy pilot program when Governor Murphy signed the bill into law on January 21, 2026. (Source: New Jersey Legislature)

The program allocates $6 million in funding distributed across three hospitals selected from different geographic regions of the state, each receiving $2 million. It also creates an 11-member Psychedelic Therapy and Research Advisory Board to oversee the program, evaluate outcomes, and advise on future policy. (Source: New Jersey Legislature)

New Jersey's approach is distinct from the service center models in Oregon and Colorado. By embedding psilocybin therapy within existing hospital systems, the state is testing whether an institutional medical framework can deliver supervised psilocybin experiences effectively — and whether that model produces the kind of safety and outcomes data that could support broader adoption.

South Dakota: Legislation Passed March 10, 2026

South Dakota passed psychedelic therapy legislation on March 10, 2026 — a notable development given the state's traditionally conservative political orientation. The passage reflects how veteran health and mental health crises are creating bipartisan support for psychedelic therapy policy in states that might not be obvious candidates for reform. (Source: South Dakota Legislature)

The details of South Dakota's regulatory framework — including whether it establishes a regulated access program or takes a more limited approach — are still being finalized. We will update this guide as implementation details become clear.

Minnesota: House Committee Approves Psilocybin Legalization Bill (March 9, 2026)

On March 9, 2026, the Minnesota House Health Finance and Policy Committee approved a bill to legalize regulated psilocybin therapy for adults 21 and older. The bill received bipartisan support in committee. (Source: Minnesota Legislature)

Key provisions of the Minnesota bill:

• Rescheduling: Would move psilocybin from Schedule I to Schedule IV under Minnesota state law
• Pilot program: Capped at 1,000 patients for the first three years of operation
• Licensed facilitators required: Patients must receive psilocybin under the supervision of a state-licensed facilitator
• Next step: The bill now heads to the Commerce Finance and Policy Committee before it can reach a full floor vote

Minnesota's approach combines elements of Oregon's facilitated model with the kind of patient caps and phased rollout that make the policy more palatable in moderate and conservative-leaning legislatures. The bill's bipartisan committee vote is a meaningful signal — it suggests the political dynamics around psilocybin therapy are shifting even in states without strong ballot-initiative traditions.

Update (July 14, 2026): The program went further than any prior Minnesota psilocybin effort — the full House adopted it 114-15 in May as an amendment to a broader health bill — but it did not survive end-of-session negotiations. In its place, lawmakers directed the Office of Cannabis Management to complete a feasibility study, with a report due January 15, 2027, laying out a framework for a therapeutic psilocybin program. Advocates view 2027 as the year to pass the access program itself. (Minnesota Reformer, July 10, 2026)

What These Developments Mean

With New Jersey's signed pilot program, South Dakota's passed legislation, and Minnesota's bill advancing through committee, the first quarter of 2026 established that psilocybin policy momentum is accelerating — not slowing. The diversity of approaches is also notable: a hospital-based pilot (New Jersey), a legislative framework (South Dakota), and a regulated therapy model with patient caps (Minnesota).

For patients in these states: these bills do not mean psilocybin therapy is immediately available. Regulatory frameworks take time to build. Follow our psilocybin FDA approval tracker for the federal developments that could eventually make prescription psilocybin available nationwide.

---

Oregon: The Pioneer (Legal Since January 2023)

Oregon made history as the first state in the nation to legalize psilocybin therapy when voters passed Measure 109 in November 2020. After a two-year regulatory development period, the Oregon Psilocybin Services program officially launched in January 2023.

How Oregon's Program Works

Oregon's model is built around supervised psilocybin experiences at licensed service centers. It is not a prescription model — you don't need a diagnosis or a doctor's referral. Adults 21 and older can access psilocybin services after completing a required preparation session with a licensed facilitator.

A typical experience follows three stages: a preparation session where the facilitator discusses intentions, medical history, and what to expect; the administration session itself, where the client consumes psilocybin mushrooms under the supervision of a facilitator at a licensed service center; and an integration session afterward to help process the experience.

Oregon by the Numbers

As of early 2026, Oregon's psilocybin program has reached meaningful scale:

• 23 operational service centers across the state
• 16,000+ clients served since the program launched in mid-2023
• 12 service center closures — a reminder that the business model remains challenging for operators
• Session costs range from $1,000 to $5,000, depending on the service center, session length, and level of facilitator support

The closures are worth noting. Running a psilocybin service center in Oregon is expensive. Facilitators must complete extensive training and licensure requirements, the sessions themselves are time-intensive (typically 5-6 hours for the administration session alone), and the facilities must meet strict regulatory standards. Insurance does not cover psilocybin services, meaning clients pay entirely out of pocket.

Despite these challenges, Oregon has proven that a regulated psilocybin therapy model can work. Over 16,000 people have now had legal, supervised psilocybin experiences — generating real-world safety and outcomes data that is informing policy decisions in other states.

Looking for a psilocybin service center in Oregon? Browse our Oregon psilocybin therapy directory for a complete list of operational service centers — or go straight to Portland psilocybin service centers for the largest selection in the state.

What's Next for Oregon

Oregon continues to refine its regulatory framework based on what it has learned in the first three years of operation. The state is closely watching how other states build their programs and whether any federal action — particularly around rescheduling or FDA approval — could reshape the landscape.

Colorado: The Expanding Frontier (Legal Since 2024)

Colorado became the second state to legalize psilocybin when voters passed Proposition 122, the Natural Medicine Health Act, in November 2022. The law went further than Oregon's measure by decriminalizing not just psilocybin but also DMT, ibogaine, and mescaline (excluding peyote) for personal use, while establishing a regulated access framework for therapeutic use.

Colorado's Regulated Access Program

Colorado's Department of Regulatory Agencies (DORA) spent over two years developing the rules for its licensed healing center program. The first licensed healing center — The Center Origin in Denver — opened its doors on April 1, 2025, marking a major milestone for the state and the broader psychedelic therapy movement.

Like Oregon, Colorado's model is based on facilitated sessions at licensed centers rather than a prescription model. However, Colorado's approach differs in several key ways. Colorado calls its facilities "healing centers" rather than "service centers." The state has also taken a phased approach to which substances are available — licensed healing centers administer psilocybin and psilocyn today, and the Natural Medicine Health Act allowed regulators to consider adding DMT, ibogaine, and mescaline (excluding peyote) after June 1, 2026. The first concrete step on that front came in May 2026, when the legislature passed an ibogaine research bill — more on that below.

Colorado by the Numbers

Colorado's program has grown rapidly since its launch:

• 34 licensed healing centers across the state as of early 2026 — nine standard and 25 micro-healing centers, with 18 more applications pending per Axios Denver's February 2026 reporting (live count updated weekly by DORA)
• Session costs range from $1,500 to $3,400, placing Colorado on the higher end of the cost spectrum compared to Oregon
• An ibogaine research pilot program was signed into law June 4, 2026 (HB26-1325), effective August 12, 2026 — the first legislated step toward Colorado becoming the first state to offer regulated access to multiple psychedelic substances

The higher cost floor in Colorado compared to Oregon likely reflects the newer market, different regulatory requirements, and the fact that operators are still establishing their business models. As the market matures and more healing centers open, prices may become more competitive.

Looking for a psilocybin healing center in Colorado? Browse our Colorado psilocybin therapy directory for a complete list of licensed healing centers — including Denver psilocybin service centers where the state's first licensed healing center opened in 2025.

The DMT/Ibogaine/Mescaline Question

One of the most watched aspects of Colorado's program is the potential expansion beyond psilocybin — and in 2026, ibogaine moved from speculation to statute. Colorado's Natural Medicine Advisory Board voted to recommend adding ibogaine to the regulated program in late 2025, and in May 2026 the legislature passed HB26-1325 with bipartisan support (56-7 in the House, 30-5 in the Senate). Signed June 4, 2026 and effective August 12, 2026, the law:

• Establishes an ibogaine research pilot program within the state's Behavioral Health Administration, with up to five pilot sites — funded through gifts, grants, and donations rather than state appropriations
• Authorizes the state's natural medicine licensing authority to adopt rules for the administration, manufacturing, and use of ibogaine in the regulated program
• Requires ibogaine licensees to establish a benefit-sharing plan with Indigenous communities, developed in consultation with those communities

To be clear about where things stand today: licensed healing centers still administer only psilocybin and psilocyn. No ibogaine (or DMT or mescaline) healing centers are licensed yet — the research pilot and rulemaking process come first. But if Colorado follows through, it would become the first jurisdiction in the world to offer regulated therapeutic access to ibogaine — a substance that has shown remarkable promise for treating opioid addiction but remains largely unavailable in clinical settings in the United States. For the full picture — the federal Schedule I status, the Nagoya Protocol sourcing obstacle, the Texas and Mississippi trials, and a plain-English cardiac safety warning — see our ibogaine legal status tracker.

This would be a significant development not just for Colorado but for the entire field of psychedelic medicine.

New Mexico: The Next State in Line

In April 2025, New Mexico's governor signed the Medical Psilocybin Act (SB 219), making New Mexico the third state to pass a comprehensive psilocybin therapy law. Unlike Oregon and Colorado, which used ballot initiatives, New Mexico's law was passed through the traditional legislative process — a model that other states are watching closely.

How New Mexico's Model Will Work

New Mexico's approach is explicitly medical. The Medical Psilocybin Act creates a framework for patients to access psilocybin therapy through licensed providers, with the goal of making the treatment available to patients by the end of 2026.

The details of New Mexico's regulatory framework are still being developed, but the medical framing is significant. While Oregon and Colorado use a "service center" or "healing center" model open to any adult, New Mexico's medical model may require a diagnosis or physician involvement — potentially making it easier for insurance coverage to follow in the future.

New Mexico's timeline is ambitious. Building a regulatory infrastructure from scratch — including licensing requirements, facility standards, facilitator training programs, and safety protocols — is a complex undertaking. But the state has the benefit of learning from Oregon's three years of operational experience and Colorado's more recent launch.

As of early 2026, New Mexico remains one of only three states — alongside Oregon and Colorado — with a legislated pathway for medical psilocybin access. The regulatory framework is still under development, but the law is on the books and implementation is moving forward.

Tracking New Mexico's program? See our New Mexico psilocybin therapy guide for a full breakdown of qualifying conditions, the DOH timeline, and how to get notified when the first licensed providers go live. We're building a New Mexico provider directory — check back soon.

Texas: A Surprise Player in Psychedelic Research

Texas may not be where you'd expect to find psychedelic reform, but the state has emerged as a significant player — particularly in psychedelic research funding.

Texas has allocated $50 million for ibogaine FDA clinical trials, making it the largest state investment in psychedelic research in the country. The funding is specifically targeted at studying ibogaine's potential for treating veterans with traumatic brain injuries and substance use disorders.

This investment is notable for several reasons. First, it represents a bipartisan approach to psychedelic medicine — Texas is a deeply conservative state, but the focus on veterans' health has created unusual political alignment. Second, it could accelerate the FDA approval process for ibogaine, potentially bringing it to market faster than it would otherwise. Third, it signals that psychedelic reform is not just a "blue state" phenomenon.

While Texas has not moved to legalize psilocybin therapy, its substantial research investment positions it as an important player in the broader psychedelic medicine landscape.

The Federal Landscape: Executive Order, Rescheduling, and FDA Approval

The federal picture changed dramatically in the second quarter of 2026. What had been a slow-moving rescheduling petition and a promising clinical program became an active, White House-directed acceleration.

Executive Order 14401: The Federal Government Leans In

On April 18, 2026, President Trump signed Executive Order 14401, "Accelerating Medical Treatments for Serious Mental Illness," published in the Federal Register on April 22 (91 FR 21709). The order directs the FDA to prioritize review of psychedelic drugs holding Breakthrough Therapy designation and contemplates DEA rescheduling review running in parallel with FDA review rather than after it.

Six days later, the FDA acted. On April 24, 2026, the agency issued three Commissioner's National Priority Vouchers to psychedelic programs — COMPASS Pathways (COMP360 psilocybin for treatment-resistant depression), Usona Institute (psilocybin for major depressive disorder), and Transcend Therapeutics (methylone for PTSD) — and granted COMPASS a rolling New Drug Application submission and review. The CNPV program's stated goal is a shortened one-to-two-month review after the NDA is filed, though both the FDA and COMPASS have characterized that timeline as a goal rather than a binding commitment.

The federal momentum continued into July. On July 13, 2026, three announcements landed in a single day: the FDA finalized its guidance for industry, "Psychedelic Drugs: Considerations for Clinical Investigations" (Federal Register notice); the FDA scheduled a public hearing on the potential future therapeutic use of psychedelic drugs for September 14, 2026, with an open public comment period; and HHS and the VA signed a five-year Memorandum of Understanding covering research, clinical development, and — if FDA approval comes — deployment of rapid-acting psychedelic therapies to veterans with serious mental health conditions.

DEA Rescheduling Petition

In August 2025, the DEA transmitted a psilocybin rescheduling petition to the Department of Health and Human Services (HHS) for scientific and medical review. This is a significant procedural step in the rescheduling process.

Psilocybin is currently classified as a Schedule I substance under the Controlled Substances Act, meaning the federal government considers it to have "no currently accepted medical use" and a "high potential for abuse." Rescheduling to Schedule II or III would acknowledge psilocybin's medical potential and could open the door to easier research, insurance coverage, and broader clinical use.

The HHS review process is not fast — it involves a thorough evaluation of the scientific evidence by the FDA and other agencies. But the fact that the petition has been transmitted is itself a signal that federal attitudes toward psilocybin are shifting.

It's worth noting that a similar rescheduling process is underway for cannabis, and the debate around that process has been contentious and slow. Psilocybin rescheduling could follow a similar trajectory, or it could move more quickly given the strength of the clinical evidence.

COMPASS Pathways COMP360: The FDA Approval Path

Perhaps the most consequential development for psilocybin therapy in the United States is COMPASS Pathways' progress toward FDA approval of COMP360, its proprietary synthetic psilocybin therapy for treatment-resistant depression.

COMPASS Pathways has now completed two successful Phase 3 clinical trials for COMP360, hitting primary endpoints in both COMP005 (June 2025) and COMP006 (February 2026). On July 7, 2026, the final piece of clinical data fell into place: positive 26-week Part B durability results from COMP006, with benefit at Week 6 maintained on average through Week 26 and serious adverse event rates comparable between the treatment and control arms. (Sources: COMPASS 8-K filing, BioSpace)

With all required clinical data now in hand, COMPASS's rolling NDA submission — underway since spring 2026, as confirmed on the company's Q1 2026 earnings call — is targeted for final submission in Q4 2026. Under the CNPV program's one-to-two-month review goal, that puts a potential FDA approval decision in late 2026 or early 2027, with the company anticipating a U.S. launch in the first half of 2027, subject to approval and DEA rescheduling of the approved formulation.

If COMP360 is approved, the implications would be enormous. It would become the first classic psychedelic approved as a prescription medicine in the United States. Psychiatrists and other qualified prescribers across the country could potentially offer psilocybin therapy to patients with treatment-resistant depression — regardless of whether their state has passed its own psilocybin legalization measure. Insurance coverage, while not guaranteed, would become a realistic possibility for the first time.

This is the development that could truly transform psilocybin from a state-by-state experiment into mainstream medicine.

For a deep dive into the full trial data, the NDA timeline, and what FDA approval would mean for insurance coverage, see our psilocybin FDA approval status tracker.

More States to Watch in 2026

Beyond the states with passed legislation, several others have active bills or emerging policy developments that could reshape the psilocybin landscape in the near term.

Iowa: Model Policy Template for Regulated Access

Iowa's regulated psilocybin program bill passed the Iowa House 84-6 in the prior session — an overwhelmingly bipartisan vote that caught the attention of national policy organizations. That bill became the basis for an ALEC model policy template that is now being adapted in other state legislatures. (Source: Iowa Legislature)

A new version of the bill has been introduced for the 2026 session. It would create a licensing board with distinct registration categories for cultivators, testing laboratories, and providers. Notably, the Iowa framework does not require a medical condition to qualify for psilocybin therapy — taking an approach closer to Oregon's open-access model than New Mexico's medical model. (Source: Iowa Legislature)

Missouri: Multiple Bills Target PTSD, Depression, and End-of-Life Care

Missouri has multiple psilocybin-related bills filed for the 2026 session. HB 1643 would allow psilocybin access for adults 21 and older diagnosed with PTSD, major depressive disorder, substance use disorders, or receiving end-of-life care. The bill is not limited to veterans — it would cover any qualifying adult. Separate bills in the Missouri legislature address ibogaine research funding. (Source: Missouri Legislature)

New Hampshire: Medical Psilocybin Bill Faces Setback

New Hampshire introduced a bill to establish a medical psilocybin program within the state's Department of Health and Human Services. A public hearing was held on January 14, 2026, but the committee recommended against the bill in February. (Source: New Hampshire Legislature)

This is an honest setback for psilocybin advocates in New Hampshire, and a reminder that legislative progress is not guaranteed even in states where bills get introduced. The committee's opposition may reflect concerns about implementation costs, regulatory complexity, or political dynamics specific to the current session. Advocates will likely reintroduce the measure in a future session.

Virginia, Kansas, and the "Trigger Law" Wave

An emerging legislative strategy — championed in part by Compass Pathways — involves state-level "trigger laws" designed to automatically reclassify psilocybin if the FDA approves a psilocybin-based therapy. (Source: Compass Pathways press releases)

Virginia became the first of these to reach a governor's desk in 2026: Governor Abigail Spanberger signed HB 1347 / SB 379 on April 13, 2026, directing the Board of Pharmacy to reschedule FDA-approved psilocybin formulations administered in healthcare settings, consistent with federal scheduling. (Source: Virginia General Assembly) In Kansas, HB 2218 — which would automatically reclassify crystalline polymorph psilocybin (the active ingredient in COMP360) to Schedule IV under state law upon FDA approval — had a committee hearing in the 2026 session. (Source: Kansas Legislature)

These trigger laws address a real gap in how federal drug scheduling works at the state level. Even if the FDA approves COMP360, individual states don't automatically update their controlled substance schedules to match. Without proactive state legislation, doctors in these states might not be able to prescribe an FDA-approved psilocybin therapy because state law still classifies psilocybin as Schedule I. The strategy has scaled quickly: per COMPASS's disclosures on its Q1 2026 earnings call, "almost 90% of the U.S. population live in a state that intends to reschedule COMP360 within 30 days after FDA approval and DEA rescheduling."

Connecticut: Pilot Expansion Signed Into Law

Connecticut converted its bill into law this session. SB 191 — which passed the Senate 35-0 on April 9 and the House 122-27 on May 6 — was signed by Governor Ned Lamont on June 4, 2026. The law expands the state's psychedelic-assisted therapy pilot program beyond veterans and first responders to any adult 18 or older who meets clinical eligibility criteria, keeps the program within FDA-approved research administered by a state medical school, and removes the provision that would have sunset the program upon federal approval of psilocybin or MDMA — positioning Connecticut to keep its program running into a post-approval world. (Bill status: Connecticut General Assembly)

Massachusetts: Framework Bill Still in Committee

Massachusetts has a psilocybin therapy framework bill active in its 2026 legislative session, still working through the committee process. Comprehensive framework legislation — rather than just a study committee or research bill — in a major northeastern state signals continued geographic expansion of the reform movement. (Source: Massachusetts Legislature)

Alaska: Ballot Initiative Filed for 2026

Activists in Alaska filed the Alaska Natural Medicine Act ballot initiative for the 2026 election cycle. If it qualifies for the ballot and passes, the measure would decriminalize and establish a regulated framework for psilocybin, DMT, and mescaline. (Source: Alaska Division of Elections)

Alaska's initiative mirrors the multi-substance approach that Colorado took with Proposition 122. If successful, it would make Alaska the first state to pass a natural medicine act since Colorado in 2022.

The Broader Trend

The 2026 legislative session confirmed what 2025 hinted at: psychedelic reform is no longer confined to a handful of progressive states. By mid-year, bills had become law in the Northeast (New Jersey's pilot in January, Connecticut's expansion in June), the South (Virginia's trigger law in April), and the Great Plains (South Dakota in March), while legislation advanced in the Midwest (Iowa, Minnesota, Missouri) and Kansas. The policy approaches are diversifying too — from open-access models to medical frameworks to FDA-triggered scheduling changes. Each year, the proposals grow more sophisticated and the political coalitions broader.

What About Ketamine? How It Fits Into the Landscape

If you're exploring psychedelic therapy options right now, it's important to understand that ketamine remains the most widely accessible psychedelic-assisted treatment in the United States. Unlike psilocybin, ketamine is already a Schedule III substance and has been used off-label for depression and other mental health conditions for years.

Hundreds of ketamine clinics operate across all 50 states, offering both in-clinic IV infusions and the FDA-approved nasal spray esketamine (Spravato). You don't need to live in Oregon or Colorado to access psychedelic-assisted therapy — ketamine clinics are likely available in your area right now.

Ready to find a ketamine clinic near you? Use our clinic directory to search by zip code and find verified providers in your state. Wondering how the cost compares to psilocybin sessions? See our guide to ketamine therapy costs across treatment types.

What This Means for Patients

If you're considering psilocybin therapy in 2026, here's a practical summary of your options:

Available now: If you're in Oregon or Colorado, you can access legal psilocybin therapy at licensed service centers and healing centers. Sessions range from $1,000 to $5,000 in Oregon and $1,500 to $3,400 in Colorado. No prescription or diagnosis is required — these are open to any adult who completes the required preparation process. Browse all psilocybin service centers in our directory to find a licensed provider near you.

Coming soon: If you're in New Mexico, the state is working toward having its medical psilocybin program operational by the end of 2026. Details on licensing, costs, and access requirements are still being developed.

Pilot program launching: New Jersey's hospital-based pilot program is funded and authorized as of January 2026. Three hospitals will be selected from different regions of the state. This is not open-access — it's a structured research-and-treatment pilot.

Legislation passed, programs building: South Dakota (March 10, 2026) has passed psilocybin legislation, and Connecticut's expanded pilot program was signed into law June 4, 2026. Minnesota came close — its psilocybin therapy program passed the full House 114-15 in May but was cut in final negotiations; a state feasibility study is due January 15, 2027, and advocates are aiming to pass the access program in 2027. Regulatory frameworks in these states are not yet operational — access is not immediately available, but the legal pathway is taking shape.

On the horizon: COMPASS Pathways expects to complete its rolling NDA submission in Q4 2026, with a potential FDA approval decision in late 2026 or early 2027 and an anticipated U.S. launch in the first half of 2027. If approved, prescription psilocybin therapy for treatment-resistant depression could become available through qualified healthcare providers — and thanks to state trigger laws, quickly in much of the country.

Available everywhere right now: Ketamine therapy is legal and available in all 50 states through hundreds of licensed clinics. If you're looking for psychedelic-assisted treatment today, ketamine is the most accessible option — and typically more affordable than most psilocybin sessions.

Looking Ahead: What to Watch in 2026-2027

The next 12 to 18 months could be the most consequential period in the history of psychedelic medicine in the United States. Here are the key developments to watch:

COMP360 FDA decision: With positive 26-week Part B data reported July 7, 2026, COMPASS Pathways targets final NDA submission in Q4 2026. Under the CNPV program's one-to-two-month review goal, an approval decision could come in late 2026 or early 2027 — a watershed moment for the entire field, with a U.S. launch anticipated in the first half of 2027.

Colorado's ibogaine rollout: HB26-1325 takes effect August 12, 2026. Watch for the Behavioral Health Administration to stand up its ibogaine research pilot sites and for the natural medicine licensing authority to begin ibogaine rulemaking — the steps that would make Colorado the first multi-substance regulated psychedelic program.

FDA's September 14 public hearing: The FDA is holding a public hearing on the potential future therapeutic use of psychedelic drugs on September 14, 2026, with an open public comment period — a window into how the agency is thinking about the post-approval landscape.

HHS review of rescheduling: The Department of Health and Human Services is reviewing the psilocybin rescheduling petition transmitted by the DEA in August 2025, and Executive Order 14401 contemplates DEA review of approved products running in parallel with FDA review. Any movement here would have far-reaching implications for research, prescribing, and insurance coverage.

New Mexico's launch: New Mexico is targeting patient access by the end of 2026. How smoothly the state stands up its medical psilocybin program will influence other states considering the legislative (rather than ballot initiative) path.

State legislatures in 2027: Minnesota's feasibility study is due January 15, 2027, teeing up another run at its access program. Iowa, Missouri, Kansas, and Massachusetts still have active bills, and Alaska's ballot initiative is aimed at the 2026 election cycle. The question is no longer whether more states will act — it's how many and how fast.

FDA trigger laws: If COMP360 wins FDA approval, states with trigger laws — Virginia's is now signed, and Kansas HB 2218 is pending — would reclassify psilocybin without additional legislative action. Per COMPASS's disclosures, nearly 90% of the U.S. population lives in a state that intends to reschedule COMP360 within 30 days of federal approval and rescheduling.

Texas ibogaine research: With $50 million in funding, Texas-backed ibogaine clinical trials could generate data that accelerates the case for ibogaine as a treatment for addiction and traumatic brain injury.

The Bottom Line

Psilocybin therapy is no longer a fringe idea or a distant possibility. It's a legal, regulated treatment option in Oregon and Colorado today, with New Mexico coming online and federal approval potentially months — not years — away.

The combination of state-level legalization, a White House executive order accelerating FDA review, and COMPASS Pathways' nearly complete NDA means that the next year could bring more change to the psychedelic therapy landscape than the previous decade combined.

We'll continue updating this guide as new developments unfold. Bookmark this page, or check back regularly for the latest information on psilocybin therapy legality across the United States.

---

Sources

• Oregon Health Authority Psilocybin Services Data Dashboard. OHA
• Colorado Department of Natural Medicine — licensed healing center directory. DORA
• COMPASS Pathways — COMP360 Phase 3 trial 2 (COMP006) primary endpoint results. Press release, February 2026
• COMPASS Pathways — COMP360 Phase 3 trial 1 (COMP005) primary endpoint results. Press release, June 2025
• New Jersey psilocybin therapy pilot program legislation — signed January 21, 2026. (Source: New Jersey Legislature)
• Minnesota House Health Finance and Policy Committee — psilocybin legalization bill approved March 9, 2026. (Source: Minnesota Legislature)
• South Dakota psilocybin therapy legislation — passed March 10, 2026. (Source: South Dakota Legislature)
• Iowa regulated psilocybin program bill — passed Iowa House 84-6 in prior session; new version introduced for 2026 session. (Source: Iowa Legislature)
• Missouri HB 1643 — psilocybin access bill filed for 2026 session. (Source: Missouri Legislature)
• New Hampshire medical psilocybin bill — public hearing January 14, 2026; committee recommended against, February 2026. (Source: New Hampshire Legislature)
• Kansas HB 2218 — psilocybin trigger law; committee hearing held in 2026 session. (Source: Kansas Legislature)
• Compass Pathways — state-level trigger law advocacy. (Source: Compass Pathways press releases)
• Alaska Natural Medicine Act ballot initiative filed for 2026. (Source: Alaska Division of Elections)
• New Mexico Medical Psilocybin Act (SB 219) — signed April 2025. (Source: New Mexico Legislature)
• Executive Order 14401, "Accelerating Medical Treatments for Serious Mental Illness" — signed April 18, 2026. Federal Register, 91 FR 21709 (April 22, 2026)
• FDA — Commissioner's National Priority Vouchers issued to three psychedelic programs; rolling NDA granted to COMPASS Pathways. FDA press release, April 24, 2026
• COMPASS Pathways — positive 26-week Part B COMP006 results, July 7, 2026. 8-K filing; BioSpace coverage
• COMPASS Pathways — Q1 2026 earnings call, May 13, 2026 (rolling NDA status; state trigger-law coverage). Motley Fool transcript
• FDA — final guidance, "Psychedelic Drugs: Considerations for Clinical Investigations," July 13, 2026. Guidance PDF; Federal Register notice
• FDA — public hearing on potential future therapeutic use of psychedelic drugs, September 14, 2026. Hearing details
• HHS and VA — five-year Memorandum of Understanding on psychedelic therapies for veterans, July 13, 2026. HHS press release
• Connecticut SB 191 — signed by Gov. Ned Lamont, June 4, 2026. Marijuana Moment; Connecticut General Assembly bill status
• Virginia HB 1347 / SB 379 — psilocybin trigger law signed by Gov. Abigail Spanberger, April 13, 2026. (Source: Virginia General Assembly)
• Minnesota — psilocybin therapy program adopted by House 114-15, May 2026. Marijuana Moment; session outcome and OCM feasibility study per Minnesota Reformer, July 10, 2026
• Colorado HB26-1325 (Natural Medicine / ibogaine research pilot) — signed June 4, 2026; effective August 12, 2026. Colorado General Assembly
• Colorado Natural Medicine Advisory Board — ibogaine recommendation. Westword
• Colorado healing center counts. Axios Denver, February 3, 2026

---

Psychedelic Beacon is a free online directory helping people find licensed ketamine clinics and psychedelic therapy providers across the United States. Search our directory to find a provider near you.

Last updated: July 14, 2026 — Mid-year refresh: Connecticut SB 191 signed (June 4), Colorado ibogaine research pilot HB26-1325 signed (June 4, effective August 12), Virginia trigger law signed (April 13), Minnesota program stalls with feasibility study due January 15, 2027, plus Executive Order 14401, the April 24 CNPV grants, July 7 COMP360 Part B results, and the July 13 federal announcements.